Rivoceranib

Generic Name
Rivoceranib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C24H23N5O
CAS Number
811803-05-1
Unique Ingredient Identifier
5S371K6132
Background

Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication

本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Associated Conditions
-
Associated Therapies
-

Study of the Combination of Apatinib and POF

Phase 2
Conditions
Interventions
First Posted Date
2018-10-16
Last Posted Date
2018-10-16
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
26
Registration Number
NCT03707639
Locations
🇨🇳

Rongbo Lin, Fuzhou, Fujian, China

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

First Posted Date
2018-10-16
Last Posted Date
2022-04-11
Lead Sponsor
Elevar Therapeutics
Target Recruit Count
12
Registration Number
NCT03707028
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma

First Posted Date
2018-10-11
Last Posted Date
2018-10-11
Lead Sponsor
Eastern Hepatobiliary Surgery Hospital
Target Recruit Count
138
Registration Number
NCT03702491
Locations
🇨🇳

xiao qing xiao qing Jiang, Shanghai, Shanghai, China

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

First Posted Date
2018-09-14
Last Posted Date
2019-01-09
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
20
Registration Number
NCT03671265
Locations
🇨🇳

Department of Radiation Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Phase 2
Completed
Conditions
Interventions
First Posted Date
2018-09-07
Last Posted Date
2019-04-16
Lead Sponsor
Rongjie Tao
Target Recruit Count
25
Registration Number
NCT03660761
Locations
🇨🇳

Neurosurgery, Shandong Cancer Hospital and Institute, Jinan, Shandong, China

Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer

First Posted Date
2018-09-07
Last Posted Date
2018-09-19
Lead Sponsor
Changzhou No.2 People's Hospital
Target Recruit Count
30
Registration Number
NCT03662035

Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies

Phase 1
Conditions
Interventions
First Posted Date
2018-08-31
Last Posted Date
2018-10-18
Lead Sponsor
China International Medical Foundation
Target Recruit Count
30
Registration Number
NCT03654612
Locations
🇨🇳

the Second Xiangya Hospital, Changsha, Hunan, China

Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer

First Posted Date
2018-08-29
Last Posted Date
2018-08-29
Lead Sponsor
Beijing Chest Hospital
Target Recruit Count
90
Registration Number
NCT03651219

A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations

Not Applicable
Conditions
Interventions
First Posted Date
2018-08-16
Last Posted Date
2018-08-16
Lead Sponsor
Hebei Medical University Fourth Hospital
Target Recruit Count
80
Registration Number
NCT03634059
Locations
🇨🇳

Junfeng Liu, Shijiazhuang, Hebei, China

© Copyright 2024. All Rights Reserved by MedPath